cAbl tyrosine kinase mediates reactive oxygen species- and caveolin-dependent AT1 receptor signaling in vascular smooth muscle: Role in vascular hypertrophy

Circulation Research

Volumn 97, Issue 8, 2005, Pages 829-836

  Ushio Fukai, Masuko ^a   Zuo, Lian ^a   Ikeda, Satoshi ^a   Tojo, Taiki ^a   Patrushev, Nikolay A ^a   Alexander, R Wayne ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; cAbl; Caveolin 1; NAD(P)H oxidase; Vascular smooth muscle

Indexed keywords

ABELSON KINASE; ACETYLCYSTEINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; CAVEOLIN; DIPHENYLIODONIUM SALT; EBSELEN; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SMALL INTERFERING RNA;

ANIMAL TISSUE; AORTA; ARTICLE; CELL FRACTIONATION; CONTROLLED STUDY; FOCAL ADHESION; HYPERTROPHY; LIPID RAFT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; RAT; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TRANSACTIVATION; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; HYPERTROPHY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE MICRODOMAINS; MICE; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHOSPHORYLATION; PROTEIN-TYROSINE-PHOSPHATASE; PROTO-ONCOGENE PROTEINS C-ABL; RATS; REACTIVE OXYGEN SPECIES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TRANS-ACTIVATION (GENETICS);

EID: 26844535733     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000185322.46009.F5     Document Type: Article

References (42)

1. Eguchi S, Inagami T. Signal transduction of angiotensin II type 1 receptor through receptor tyrosine kinase. Regul Pept. 2000;91:13-20.
2. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494-501.
3. Ushio-Fukai M, Alexander RW, Akers M, Griendling KK. p38MAP kinase is a critical component of the redox-sensitive signaling pathways by angiotensin II: role in vascular smooth muscle cell hypertrophy. J Biol Chem. 1998;273:15022-15029.
4. Ushio-Fukai M, Alexander RW, Akers M, Yin Q, Fujio Y, Walsh K, Griendling KK. Reactive oxygen species mediate the activation of Akt/Protein kinase B by angiotensin II in vascular smooth muscle cells. J Biol Chem. 1999;274:22699-22704.
5. Ushio-Fukai M, Griendling KK, Becker PL, Hilenski L, Halleran S, Alexander RW. Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2001;21:489-495.
6. Ishizaka N, Griendling KK, Lassegue B, Alexander RW. Angiotensin II type 1 receptor: relationship with caveolae and caveolin after initial agonist stimulation. Hypertension. 1998;32:459-466.
7. Ushio-Fukai M, Hilenski L, Santanam N, Becker PL, Ma Y, Griendling KK, Alexander RW. Cholesterol depletion inhibits epidermal growth factor receptor transactivation by angiotensin II in vascular smooth muscle cells: role of cholesterol-rich microdomains and focal adhesions in angiotensin II signaling. J Biol Chem. 2001;276:48269-48275.
8. Zuo L, Ushio-Fukai M, Hilenski LL, Alexander RW. Microtubules regulate angiotensin II type 1 receptor and racl localization in caveolae/lipid rafts. Arterioscler Thromb Vasc Biol. 2004;24:1-7.
9. Plattner R, Kadlec L, DeMali KA, Kazlauskas A, Pendergast AM. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev. 1999;13:2400-2411.
10. Furstoss O, Dorey K, Simon V, Barila D, Superti-Furga G, Roche S. c-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis. Embo J. 2002;21:514-524.
11. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340: 1330-1340.
12. Van Etten RA. Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell Biol. 1999;9:179-186.
13. Tybulewicz VL, Crawford CE, Jackson PK, Bronson RT, Mulligan RC. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell. 1991;65:1153-1163.
14. Lewis JM, Baskaran R, Taagepera S, Schwartz MA, Wang JY. Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc Natl Acad Sci USA. 1996;93:15174-15179.
15. Woodring PJ, Hunter T, Wang JY. Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases. J Cell Sci. 2003;116:2613-2626.
16. Sun X, Majumder P, Shioya H, Wu F, Kumar S, Weichselbaum R, Kharbanda S, Kufe D. Activation of the cytoplasmic c-Abl tyrosine kinase by reactive oxygen species. J Biol Chem. 2000;275:17237-17240.
17. Kumar S, Bharti A, Mishra NC, Raina D, Kharbanda S, Saxena S, Kufe D. Targeting of the c-Abl tyrosine kinase to mitochondria in the necrotic cell death response to oxidative stress. J Biol Chem. 2001;276:17281-17285.
18. Sangumetti AR, Mastick CC. c-Abl is required for oxidative stress-induced phdsphorylation of caveolin-1 on tyrosine 14. Cell Signal. 2003;15:289-298.
19. Evans JP, Wickremasinghe RG, Hoffbrand AV. Tyrosine protein kinase substrates in Philadelphia-positive human chronic granulocytic leukemia derived cell lines (K562 and BV173): detection by using an immunoblotting technique. Leukemia. 1987;1:524-525.
20. Smart EJ, Ying Y-S, Mineo C, Anderson RGW. A detergent-free method for purifying caveolae membrane from tissue culture cells. Proc Natl Acad Sci USA. 1995;92:10104-10108.
21. Yano H, Cong F, Birge RB, Goff SP, Chao MV. Association of the Abl tyrosine kinase with the Trk nerve growth factor receptor. J Neurosci Res. 2000;59:356-364.
22. Plattner R, Irvin BJ, Guo S, Blackburn K, Kazlauskas A, Abraham RT, York JD, Pendergast AM. A new link between the c-Abl tyrosine kinase and phosphoinositide signalling through PLC-gammal. Nat Cell Biol. 2003;5:309-319.
23. c-src antibodies inhibits the angiotensin II activation of phospholipase C-γ1 in rat aortic smooth muscle cells. J Biol Chem. 1995;270:15734-15738.
24. Ishida M, Marrero MB, Schieffer B, Ishida T, Bernstein KE, Berk BC. Angiotensin II activates pp60c-src in vascular smooth muscle cells. Circ Res. 1995;77:1053-1059.
25. Koch A, Mancini A, Stefan M, Niedenthal R, Niemann H, Tamura T. Direct interaction of nerve growth factor receptor, TrkA, with nonreceptor tyrosine kinase, c-Abl, through the activation loop. FEBS Lett. 2000;469:72-76.
26. Yu HH, Zisch AH, Dodelet VC, Pasquale EB. Multiple signaling interactions of Ab1 and Arg kinases with the EphB2 receptor. Oncogene. 2001;20:3995-4006.
27. Glover RT, Angiolieri M, Kelly S, Monaghan DT, Wang JY, Smithgall TE, Buller AL. Interaction of the N-methyl-D-aspartic acid receptor NR2D subunit with the c-Abl tyrosine kinase. J Biol Chem. 2000;275: 12725-12729.
28. Marrero MB, Venema VJ, Ju H, Eaton DC, Venema RC. Regulation of angiotensin II-induced JAK2 tyrosine phosphorylation: roles of SHP-1 and SHP-2. Am J Physiol. 1998;275:C1216-1223.
29. Seta K, Sadoshima J. Phosphorylation of tyrosine 319 of the angiotensin II type 1 receptor mediates angiotensin II-induced trans-activation of the epidermal growth factor receptor. J Biol Chem. 2003;278:9019-9026.
30. Doan T, Farmer P, Cooney T, Ali MS. Selective down-regulation of angiotensin II receptor type 1A signaling by protein tyrosine phosphatase SHP-2 in vascular smooth muscle cells. Cell Signal. 2004;16:301-311.
31. Meng TC, Fukada T, Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell. 2002;9:387-399.
32. Kim YN, Wiepz GJ, Guadarrama AG, Bertics PJ. Epidermal growth factor-stimulated tyrosine phosphorylation of caveolin-1: enhanced caveolin-1 tyrosine phosphorylation following aberrant epidermal growth factor receptor status. J Biol Chem. 2000;275:7481-7491.
33. Labrecque L, Royal I, Surprenant DS, Patterson C, Gingras D, Beliveau R. Regulation of vascular endoflielial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol Biol Cell. 2003;14:334-347.
34. Ikeda S, Ushio-Fukai M, Zuo L, Tojo T, Alexander RW. Novel role of ARF6 in vascular endothelial growth factor signaling and angiogenesis. Circ Res. 2005;96:467-475.
35. Lee H, Volonte D, Galbiati F, Iyengar P, Lublin DM, Bregman DB, Wilson MT, Campos-Gonzalez R, Bouzahzah B, Pestell RG, Scherer PE, Lisanti MP. Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav- 1/Grb7 signaling cassette. Mol Endocrinol. 2000;14:1750-1775.
36. Cao H, Courchesne WE, Mastick CC. A phosphotyrosine-dependent protein interaction screen reveals a role for phosphorylation of caveolin-1 on tyrosine 14: recruitment of C-terminal Src kinase. J Biol Chem. 2002;277:8771-8774.
37. Giancotti FG, Ruoslahti E. Integrin signaling. Science. 1999;285: 1028-1032.
38. Eguchi S, Iwasaki H, Hirata Y, Frank GD, Motley ED, Yamakawa T, Numaguchi K, Inagami T. Epidermal growth factor receptor is indispensable for c-Fos expression and protein synthesis by angiotensin II. Eur J Pharmacol. 1999;376:203-206.
39. Zuo L, Ushio-Fukai M, Ikeda S, Hilenski L, Patrushev NA, Alexander RW. Caveolin-1 is essential for activation of Rac1 and NAD(P)H oxidase following AT1R stimulation: role in redox signaling and vascular hypertrophy. Arterioscler Thromb Vasc Biol. 2005;25:1824-1830.
40. Kelly DJ, Cox AJ, Gow RM, Zhang Y, Kemp BE, Gilbert RE. Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo. Hypertension. 2004;44:195-202.
41. Lassila M, Allen TJ, Cao Z, Thallas V, Jandeleit-Dahm KA, Candido R, Cooper ME. Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:935-942.
42. Candido R, Allen TJ, Lassila M, Cao Z, Thallas V, Cooper ME, Jandeleit-Dahm KA. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation. 2004;109:1536-1542.